Take Action
Home | Faculty & Research Overview | Research
Research Details
Vioxx: Too Risky for Merck?
Abstract
This case follows Merck's pharmaceutical product, Vioxx, from initial development to launch and subsequent withdrawal, and considers the decisions made at each stage by the Merck executives involved. The case concludes by examining the financial impact of the Vioxx withdrawal on the company and on the Merck stock value.
Type
Case
Author(s)
Mitchell A. Petersen, Rashmi Singhal
Date Published
01/01/2007
Citations
Petersen, Mitchell A., and Rashmi Singhal. Vioxx: Too Risky for Merck?. Case 5-207-253 (KEL289).
PREVIEW or BUYKELLOGG INSIGHT
Explore leading research and ideas
Find articles, podcast episodes, and videos that spark ideas in lifelong learners, and inspire those looking to advance in their careers.
learn more
COURSE CATALOG
Review Courses & Schedules
Access information about specific courses and their schedules by viewing the interactive course scheduler tool.
LEARN MORE
DEGREE PROGRAMS
Discover the path to your goals
Whether you choose our Full-Time, Part-Time or Executive MBA program, you’ll enjoy the same unparalleled education, exceptional faculty and distinctive culture.
learn more